Darbepoetin α as treatment for anemia in patients receiving chemotherapy: A single-center experience

Anti-Cancer Drugs

Volumn 16, Issue 6, 2005, Pages 617-620

  Bartsch, Rupert ^a   Wenzel, Catharina ^a   Sevelda, Ursula ^a   Hussian, Dagmar ^a   Pluschnig, Ursula ^a   Locker, Gottfried J ^a   Mader, Robert ^a   Zielinski, Christoph C ^a   Steger, Guenther G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chemotherapy induced anemia; Darbepoetin ; Fatigue; Quality of life

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; FATIGUE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; ERYTHROPOIETIN; FATIGUE; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 20844441762     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200507000-00004     Document Type: Article

References (13)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616-1634.
2. Tchekmedyian NS. Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology 2002; 16:17-24.
3. Dubray B, Mosseri V, Brunin F. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 1996; 201:553-558.
4. Valley AW. Overview of cancer-related anemia: focus on the potential role of darbepoetin alfa. Pharmacotherapy 2002; 22:1503-1593.
5. Osterberg A. New erythropoietic proteins: rationale and clinical data. Semin Oncol 2004; 31:12-18.
6. Steensma DP. Management of anemia in patients with cancer. Curr Oncol Rep 2004; 6:297-304.
7. Tchekmedyian NS, Kallich J, McDermott A. The relationship between psychologic distress and cancer related fatigue. Cancer 2003; 98: 198-203.
8. Egrie JC, Dweyer E, Browne JK. Darbepoetin alfa has a longer circulating half-life and a greater in vivo potency than recombinant humane erythropoietin. Exp Hematol 2003; 31:290-299.
9. Glaspy JA. Hematopoietic management in oncology practice. Oncology 2003; 17:1724-1730.
10. Sheffield R, Sullivan D, Saltiel E. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 1997; 31:1094-1095.
11. Cvetkovic RS, Goa KL. Darbepoetin α: in patients with chemotherapy related anemia. Drugs 2003; 63:1067-1074.
12. Joy MS. Darbepoetin α: a novel erythropoiesis-stimulating protein. Ann Pharmacother 2002; 36:1183-1192.
13. Vansteenkiste J, Tomita D, Rossi G. Darbepoetin α in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anemia at baseline. Support Care Cancer 2004; 12:253-262.